735 related articles for article (PubMed ID: 25712124)
21. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
24. Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors.
Shoeb M; Ramana KV; Srivastava SK
Free Radic Biol Med; 2013 Oct; 63():280-90. PubMed ID: 23732517
[TBL] [Abstract][Full Text] [Related]
25. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
[TBL] [Abstract][Full Text] [Related]
26. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
27. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
[TBL] [Abstract][Full Text] [Related]
28. Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
[TBL] [Abstract][Full Text] [Related]
29. Cytoplasmic levels of cFLIP determine a broad susceptibility of breast cancer stem/progenitor-like cells to TRAIL.
French R; Hayward O; Jones S; Yang W; Clarkson R
Mol Cancer; 2015 Dec; 14():209. PubMed ID: 26667821
[TBL] [Abstract][Full Text] [Related]
30. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
31. ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells.
Yuan X; Kho D; Xu J; Gajan A; Wu K; Wu GS
Oncotarget; 2017 Mar; 8(13):21626-21638. PubMed ID: 28423492
[TBL] [Abstract][Full Text] [Related]
32. T63, a new 4-arylidene curcumin analogue, induces cell cycle arrest and apoptosis through activation of the reactive oxygen species-FOXO3a pathway in lung cancer cells.
Liu H; Zhou BH; Qiu X; Wang HS; Zhang F; Fang R; Wang XF; Cai SH; Du J; Bu XZ
Free Radic Biol Med; 2012 Dec; 53(12):2204-17. PubMed ID: 23085518
[TBL] [Abstract][Full Text] [Related]
33. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
[TBL] [Abstract][Full Text] [Related]
35. ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.
Parker CS; Zhou L; Prabhu VV; Lee S; Miner TJ; Ross EA; El-Deiry WS
Am J Cancer Res; 2023; 13(12):6290-6312. PubMed ID: 38187068
[TBL] [Abstract][Full Text] [Related]
36. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
[TBL] [Abstract][Full Text] [Related]
37. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
[TBL] [Abstract][Full Text] [Related]
38. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.
Sharon C; Baranwal S; Patel NJ; Rodriguez-Agudo D; Pandak WM; Majumdar AP; Krystal G; Patel BB
Oncotarget; 2015 Jun; 6(17):15332-47. PubMed ID: 25895029
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway.
Feng X; Jiang J; Shi S; Xie H; Zhou L; Zheng S
Int J Oncol; 2016 Dec; 49(6):2600-2610. PubMed ID: 27840896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]